Expertise in
16
conditions

Dr. Karen L. Fink

Neurology
Healthtexas Provider Network
4001 Worth St, 
Dallas, TX 
 (1034.7 mi)
Accepting New Patients
Expertise in
16
conditions
Healthtexas Provider Network
4001 Worth St, 
Dallas, TX 
 (1034.7 mi)
OverviewInsuranceLocationsClinical Research

Overview

Karen Fink is a Neurologist in Dallas, Texas. Dr. Fink is highly rated in 16 conditions, according to our data. Her top areas of expertise are Astrocytoma, Glioblastoma, Glioma, and Brain Tumor. Dr. Fink is currently accepting new patients.

Her clinical research consists of co-authoring 17 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Neurology
Licenses
Psychiatry & Neurology in TX
Languages Spoken
English
Gender
Female

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Blue Cross Blue Shield
  •  Scott and White Health

Locations

HEALTHTEXAS PROVIDER NETWORK
4001 Worth St, Dallas, TX 75246
Other Locations
HEALTHTEXAS PROVIDER NETWORK
821 N Coleman St, Suite 100, Prosper, TX 75078
HEALTHTEXAS PROVIDER NETWORK
3410 Worth St, 820 Baylor Scott White, Dallas, TX 75246
HEALTHTEXAS PROVIDER NETWORK
4708 Alliance Blvd, Plano, TX 75093

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Multicenter, Open-Label Study With a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy
A Multicenter, Open-Label Study With a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy
Enrollment Status: Active_not_recruiting
Publish Date: June 21, 2024
Intervention Type: Drug
Study Drugs: Berubicin, Lomustine
Study Phase: Phase 2
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Enrollment Status: Suspended
Publish Date: April 03, 2024
Intervention Type: Biological
Study Phase: Phase 3
A Phase 1a/1b Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
A Phase 1a/1b Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
Enrollment Status: Completed
Publish Date: March 09, 2022
Intervention Type: Biological
Study Phase: Phase 1
Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate With Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects
Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate With Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects
Enrollment Status: Terminated
Publish Date: July 22, 2021
Intervention Type: Drug, Other
Study Phase: Phase 3
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Enrollment Status: Terminated
Publish Date: February 07, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2/Phase 3
A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma
A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: October 23, 2018
Intervention Type: Drug
Study Phase: Phase 3
View 5 Less Clinical Trials

17 Total Publications

Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.
Journal: JAMA oncology
Published: November 17, 2022
Similar Doctors
Expertise in
62
conditions
Dr. Vikram G. Shakkottai
Neurology
Expertise in
62
conditions
Dr. Vikram G. Shakkottai
Neurology

University Of Texas Southwestern Medical Center At Dallas

5303 Harry Hines Blvd, Fl 6, 
Dallas, TX 
 (3.9 mi)
214-645-2020
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Vikram Shakkottai is a Neurologist in Dallas, Texas. Dr. Shakkottai is highly rated in 62 conditions, according to our data. His top areas of expertise are Olivopontocerebellar Atrophy, Spinocerebellar Ataxia, Spinocerebellar Ataxia Type 1, and Drug Induced Dyskinesia. Dr. Shakkottai is currently accepting new patients.

Expertise in
11
conditions
Dr. Benjamin M. Greenberg
Neurology
Expertise in
11
conditions
Dr. Benjamin M. Greenberg
Neurology

University Of Texas Southwestern Medical Center At Dallas

5303 Harry Hines Blvd, 
Dallas, TX 
 (3.9 mi)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Benjamin Greenberg is a Neurologist in Dallas, Texas. Dr. Greenberg is highly rated in 11 conditions, according to our data. His top areas of expertise are Optic Neuritis, Neuromyelitis Optica, Multiple Sclerosis (MS), Transverse Myelitis, and Deep Brain Stimulation. Dr. Greenberg is currently accepting new patients.

Expertise in
15
conditions
Dr. Steven A. Vernino
Neurology
Expertise in
15
conditions
Dr. Steven A. Vernino
Neurology

University Of Texas Southwestern Medical Center At Dallas

6201 Harry Hines Blvd, 
Dallas, TX 
 (4.6 mi)
214-645-8300
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Steven Vernino is a Neurologist in Dallas, Texas. Dr. Vernino is highly rated in 15 conditions, according to our data. His top areas of expertise are Familial Dysautonomia, Orthostatic Hypotension, Low Blood Pressure, Postural Orthostatic Tachycardia Syndrome (POTS), and Nerve Decompression. Dr. Vernino is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile